Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials
Abstract Itepekimab is a monoclonal antibody that targets interleukin (IL‐33) and has been shown to reduce airway inflammation and associated tissue damage in preclinical studies. We assessed the safety, tolerability, pharmacokinetics (PKs), and pharmacodynamic profiles of single‐ascending and multi...
Saved in:
Main Authors: | Matthew P. Kosloski (Author), George D. Kalliolias (Author), Christine R. Xu (Author), Sivan Harel (Author), Ching‐Ha Lai (Author), Wenjun Zheng (Author), John D. Davis (Author), Mohamed A. Kamal (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials
by: Matthew P. Kosloski, et al.
Published: (2024) -
Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study
by: Andrew Gewitz, et al.
Published: (2024) -
Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
by: B Wang, et al.
Published: (2017) -
Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
by: Joo Young Na, et al.
Published: (2022) -
First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers
by: Fei Tang, et al.
Published: (2023)